- Home
- REVBW vs PFSI Comparison
REVBW vs PFSI Comparison
Compare REVBW & PFSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- PFSI
- Stock Information
- Founded
- REVBW N/A
- PFSI 2008
- Country
- REVBW United States
- PFSI United States
- Employees
- REVBW 9
- PFSI N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- PFSI Finance: Consumer Services
- Sector
- REVBW Health Care
- PFSI Finance
- Exchange
- REVBW Nasdaq
- PFSI Nasdaq
- Market Cap
- REVBW N/A
- PFSI 5.1B
- IPO Year
- REVBW 2020
- PFSI 2013
- Fundamental
- Price
- REVBW $0.01
- PFSI $106.75
- Analyst Decision
- REVBW
- PFSI Buy
- Analyst Count
- REVBW 0
- PFSI 8
- Target Price
- REVBW N/A
- PFSI $101.38
- AVG Volume (30 Days)
- REVBW N/A
- PFSI 228.3K
- Earning Date
- REVBW N/A
- PFSI 10-24-2024
- Dividend Yield
- REVBW N/A
- PFSI 0.84%
- EPS Growth
- REVBW N/A
- PFSI N/A
- EPS
- REVBW N/A
- PFSI 3.66
- Revenue
- REVBW N/A
- PFSI $1,915,995,000.00
- Revenue This Year
- REVBW N/A
- PFSI N/A
- Revenue Next Year
- REVBW N/A
- PFSI $25.01
- P/E Ratio
- REVBW N/A
- PFSI $29.17
- Revenue Growth
- REVBW N/A
- PFSI 11.61
- 52 Week Low
- REVBW N/A
- PFSI $62.15
- 52 Week High
- REVBW N/A
- PFSI $109.34
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- PFSI 63.96
- Support Level
- REVBW N/A
- PFSI $101.90
- Resistance Level
- REVBW N/A
- PFSI $109.34
- Average True Range (ATR)
- REVBW 0.00
- PFSI 2.17
- MACD
- REVBW 0.00
- PFSI 0.61
- Stochastic Oscillator
- REVBW 0.00
- PFSI 78.27
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About PFSI PennyMac Financial Services Inc.
PennyMac Financial Services Inc is a United States-based financial services company primarily engaged in mortgage lending. The company operates through three segments: production, servicing, and investment management. The company's production and servicing segment together form the mortgage banking business that includes mortgage loan origination, acquisition, and sale activities; while the investment management segment includes investment manager's activities, such as performing diligence, and managing acquired assets. The company generates the majority of revenue from its mortgage banking business.